Results 271 to 280 of about 38,769 (305)
Some of the next articles are maybe not open access.
Risk of DKA with SGLT2 inhibitors
Drug and Therapeutics Bulletin, 2021Abstract Overview of: Douros A, Lix LM, Fralick M, et al. Sodium-glucose cotransporter-2 inhibitors and the risk for diabetic ketoacidosis. Ann Intern Med 2020;173:417–25.
openaire +2 more sources
SGLT2 Inhibitors and Mechanisms of Hypertension
Current Cardiology Reports, 2018We sought to review currently available data on the safety and efficacy of sodium-glucose cotransporter 2 (SGLT2) inhibitors in type 2 diabetes mellitus patients with hypertension.Inhibition of SGLT2 in the renal proximal tubule results in increased urinary glucose excretion and modest improvements of hemoglobin A1C.
Alexandros, Briasoulis +2 more
openaire +2 more sources
Abstract SGLT2 inhibitors were first introduced for heart failure in 2020 and are now first-line agents for all patients with symptomatic heart failure regardless of left ventricular ejection fraction. They reduce both morbidity and mortality in clinical trials with an average relative risk reduction of 23% for heart failure ...
Roy S. Gardner +3 more
openaire +2 more sources
Roy S. Gardner +3 more
openaire +2 more sources
Journal of the American College of Cardiology, 2021
Richard K. Cheng +5 more
openaire +2 more sources
Richard K. Cheng +5 more
openaire +2 more sources
Nihon rinsho. Japanese journal of clinical medicine, 2016
SGLT2 is a glucose transporter which plays an important role for reabsorption of urinary glucose depending on the sodium concentration gradient. SGLT2 is mainly present in apical site of S1 segment of renal proximal tubule and accounts for approximately 90% of total urinary glucose reabsorption. SLC5a2, which codes SGLT2, is also known as the causative
Naoto, Kubota, Takashi, Kadowaki
openaire +1 more source
SGLT2 is a glucose transporter which plays an important role for reabsorption of urinary glucose depending on the sodium concentration gradient. SGLT2 is mainly present in apical site of S1 segment of renal proximal tubule and accounts for approximately 90% of total urinary glucose reabsorption. SLC5a2, which codes SGLT2, is also known as the causative
Naoto, Kubota, Takashi, Kadowaki
openaire +1 more source
SGLT2 inhibitors: are they safe?
Postgraduate Medicine, 2017Sodium-glucose linked transporter type 2 (SGLT2) inhibitors are a relatively new class of antidiabetic drugs with positive cardiovascular and kidney effects. The aim of this review is to present the safety issues associated with SGLT2 inhibitors. Urogenital infections are the most frequently encountered adverse events, although tend to be mild to ...
Sebastian Filippas-Ntekouan +2 more
openaire +2 more sources
An update on the safety of SGLT2 inhibitors
Expert Opinion on Drug Safety, 2019Sodium-glucose cotransporter type 2 inhibitors (SGLT2is) are recommended after metformin for a large spectrum of patients with type 2 diabetes, because of a favorable benefit/risk profile despite a variety of adverse events.This narrative review discusses the safety profile of SGLT2is: initial concerns (cardiovascular safety, acute renal failure ...
openaire +2 more sources
Carcinogenicity in rats of the SGLT2 inhibitor canagliflozin
Chemico-Biological Interactions, 2014The carcinogenicity potential of canagliflozin, an inhibitor of SGLT2, was evaluated in a 2-year rat study (10, 30, and 100 mg/kg). Rats showed an increase in pheochromocytomas, renal tubular tumors, and testicular Leydig cell tumors. Systemic exposure multiples at the highest dose relative to the maximum clinical dose were 12- to 21-fold ...
Sandra, De Jonghe +8 more
openaire +2 more sources